시장보고서

상품코드

1611207

종양괴사인자(TNF) 억제제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 판매 채널별, 지역별, 부문별 예측(2025-2030년)

Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Trends Analysis Report By Product (Humira, Enbrel Remicade, Simponi/Simponi Aria, Cimzia), By Application, By Sales Channel, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2024년 11월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

종양괴사인자(TNF) 억제제 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 종양괴사인자(TNF) 억제제 시장 규모는 2025-2030년 CAGR 2.2%로 2030년까지 266억 달러에 달할 것으로 추정됩니다. 에 달할 것으로 예상하고 있습니다.

자가 면역 질환의 유병률 증가, 급속한 기술 발전, 세계 의료비 증가는 성장을 촉진할 것으로 예상되는 주요 요인 중 일부입니다.

현재 시장에는 휴미라(아달리무맙), 엔브렐(에타너셉트), 레미케이드(인플릭시맙), 심포니/심포니 아리아(골리무맙), Cimzia(셀트리주맙) 등 5가지 TNF 억제제가 승인되어 있습니다. 휴미라, 엔브렐, 레미케이드의 바이오시밀러가 출시되어 시장에 큰 패러다임의 변화를 가져왔습니다.

바이오시밀러의 물결은 생물학적 제제 판매에 큰 내적 위협이 되고 있는데, 바이오시밀러는 오리지널 의약품에 필적하는 효율을 가지고 있기 때문입니다. 바이오시밀러는 비용 효율성이 높기 때문에 경제적으로 민감한 지역에서는 매력적인 선택이 될 수 있습니다. 또한 인도, 중국, 한국 등 신흥국들이 바이오시밀러 시장에 적극적으로 진출하고 있습니다.

TNF 억제제 치료와 관련된 주요 치료 영역에는 류마티스 관절염, 건선, 건선성 관절염, 크론병, 궤양성 대장염 등이 포함됩니다. 이들 의약품은 주로 자가면역질환 치료에 사용되지만, 현재 진행 중인 여러 연구에서 암 및 기타 염증성 질환 치료에 TNF 억제제의 역할을 연구하고 있습니다.

TNF 억제제 분야의 주요 기업 중 일부는 제품 공동개발을 위한 인수합병(M&A), 합작투자 등 전략적 이니셔티브에 참여하고 있습니다. 또한, 제조사 간 특허 침해 문제도 시장 경쟁을 심화시키고 있습니다. 예를 들어, 애브비는 베링거인겔하임과 휴미라의 지적재산권(IP) 문제를 해결했습니다. 이 계약을 통해 베링거인겔하임은 미국에서 휴미라의 지적재산권에 대한 비독점적 라이선스를 취득했습니다.

종양괴사인자(TNF) 억제제 시장 보고서 하이라이트

제품별로는 다양한 자가면역질환에 대한 효능이 입증되며 환자와 의료진 사이에서 강한 신뢰를 쌓은 휴미라가 2024년 40.5%의 최대 매출 점유율로 시장을 석권했습니다.
2024년 류마티스 관절염은 전 세계적으로 높은 유병률로 인해 17.51%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다.
온라인 약국은 디지털 플랫폼에 대한 쉬운 접근성, 원활한 주문, 정시 배송, 저렴한 가격으로 인해 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다.

용도 시장 점유율(2024년·2030년)
용도 부문 대시보드
시장 규모와 예측 및 동향 분석, 용도별(2018-2030년)
류마티스 관절염
건선
건선성 관절염
크론병
궤양성 대장염
궤양성 대장염 : 시장 매출 추정과 예측(2018-2030년)
강직성 척추염
소아 특발성 관절염
화농성 한선염
기타

제6장 종양괴사인자(TNF) 억제제 시장 : 판매 채널 추정·동향 분석

판매 채널 시장 점유율(2024년·2030년)
판매 채널 부문 대시보드
시장 규모와 예측 및 동향 분석, 판매 채널별(2018-2030년)
원내 약국
전문 약국
온라인 약국

제7장 종양괴사인자(TNF) 억제제 시장 : 지역 추정·동향 분석

지역별 시장 점유율 분석(2024년·2030년)
지역 시장 대시보드
시장 규모와 예측 동향 분석(2018-2030년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트

제8장 경쟁 구도

진출 기업 개요
기업의 시장 포지션 분석
기업 분류
전략 매핑
기업 개요/상장 기업
- AbbVie, Inc.
- Amgen, Inc.
- Johnson & Johnson Services, Inc.
- UCB SA
- Pfizer, Inc.
- Novartis International AG
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Merck &Co., Inc.

ksm 25.01.06

Tumor Necrosis Factor Inhibitor Drugs Market Growth & Trends:

The global tumor necrosis factor inhibitor drugs market size is estimated to reach USD 26.6 billion by 2030, registering a CAGR of 2.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.

Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market.

The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market.

Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions.

Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira's intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira's IP in the U.S.- scheduled to begin in July 2023.

Tumor Necrosis Factor Inhibitor Drugs Market Report Highlights:

By product, the humira segment dominating the market with the largest revenue share of 40.5% in 2024, due to its proven effectiveness in treating various autoimmune disorders, which fostered strong trust among patients and healthcare providers.
In 2024, Rheumatoid arthritis dominated the market and accounted for the largest revenue share of 17.51%, due to its high prevalence globally.
The online pharmacy is expected to grow at the highest CAGR over the forecasted period, due to easy access to digital platforms, smooth ordering, in time delivery, and affordable pricing.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Tumor Necrosis Factor Inhibitor Drugs Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Tumor Necrosis Factor Inhibitor Drugs Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Tumor Necrosis Factor Inhibitor Drugs Market: Product Estimates & Trend Analysis

4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Humira
- 4.4.1. Humira Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Enbrel
- 4.5.1. Enbrel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Remicade
- 4.6.1 Remicade Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Simponi/Simponi Aria
- 4.7.1 Simponi/Simponi Aria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Cimzia
- 4.8.1 Cimzia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Biosimilars
- 4.9.1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Tumor Necrosis Factor Inhibitor Drugs Market: Application Estimates & Trend Analysis

5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Rheumatoid Arthritis
- 5.4.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Psoriasis
- 5.5.1. Psoriasis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Psoriatic Arthritis
- 5.6.1. Psoriatic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Crohn's Disease
- 5.7.1. Crohn's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Ulcerative Colitis
5.9. Ulcerative Colitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Psoriatic Arthritis
5.10. Ankylosing Spondylitis
- 5.10.1. Ankylosing Spondylitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.11. Juvenile Idiopathic Arthritis
- 5.11.1. Juvenile Idiopathic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.12. Hidradenitis suppurativa
- 5.12.1. Hidradenitis suppurativa Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.13. Others
- 5.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel Estimates & Trend Analysis

6.1. Sales Channel Market Share, 2024 & 2030
6.2. Sales Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacy
- 6.4.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Speciality Pharmacy
- 6.5.1. Speciality Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Online Pharmacy
- 6.6.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Tumor Necrosis Factor Inhibitor Drugs Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
- 7.4.1. North America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework
  - 7.4.2.3. Competitive Insights
  - 7.4.2.4. U.S. Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework
  - 7.4.3.3. Competitive Insights
  - 7.4.3.4. Canada Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Regulatory Framework
  - 7.4.4.3. Competitive Insights
  - 7.4.4.4. Mexico Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
- 7.5.1. Europe Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework
  - 7.5.2.3. Competitive Insights
  - 7.5.2.4. UK Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework
  - 7.5.3.3. Competitive Insights
  - 7.5.3.4. Germany Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework
  - 7.5.4.3. Competitive Insights
  - 7.5.4.4. France Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework
  - 7.5.5.3. Competitive Insights
  - 7.5.5.4. Italy Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework
  - 7.5.6.3. Competitive Insights
  - 7.5.6.4. Spain Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework
  - 7.5.7.3. Competitive Insights
  - 7.5.7.4. Denmark Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework
  - 7.5.8.3. Competitive Insights
  - 7.5.8.4. Sweden Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Regulatory Framework
  - 7.5.9.3. Competitive Insights
  - 7.5.9.4. Norway Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework
  - 7.6.2.3. Competitive Insights
  - 7.6.2.4. China Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Japan
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework
  - 7.6.3.3. Competitive Insights
  - 7.6.3.4. Japan Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework
  - 7.6.4.3. Competitive Insights
  - 7.6.4.4. India Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework
  - 7.6.5.3. Competitive Insights
  - 7.6.5.4. South Korea Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework
  - 7.6.6.3. Competitive Insights
  - 7.6.6.4. Australia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Regulatory Framework
  - 7.6.7.3. Competitive Insights
  - 7.6.7.4. Thailand Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework
  - 7.7.2.3. Competitive Insights
  - 7.7.2.4. Brazil Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework
  - 7.7.3.3. Competitive Insights
  - 7.7.3.4. Argentina Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework
  - 7.8.2.3. Competitive Insights
  - 7.8.2.4. South Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework
  - 7.8.3.3. Competitive Insights
  - 7.8.3.4. Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework
  - 7.8.4.3. Competitive Insights
  - 7.8.4.4. UAE Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. AbbVie, Inc.
  - 8.5.1.1. Participant's Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Recent Developments/ Strategic Initiatives
- 8.5.2. Amgen, Inc.
  - 8.5.2.1. Participant's Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Recent Developments/ Strategic Initiatives
- 8.5.3. Johnson & Johnson Services, Inc.
  - 8.5.3.1. Participant's Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Recent Developments/ Strategic Initiatives
- 8.5.4. UCB S.A.
  - 8.5.4.1. Participant's Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Recent Developments/ Strategic Initiatives
- 8.5.5. Pfizer, Inc.
  - 8.5.5.1. Participant's Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Recent Developments/ Strategic Initiatives
- 8.5.6. Novartis International AG
  - 8.5.6.1. Participant's Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Recent Developments/ Strategic Initiatives
- 8.5.7. Boehringer Ingelheim Pharmaceuticals, Inc.
  - 8.5.7.1. Participant's Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Recent Developments/ Strategic Initiatives
- 8.5.8. Merck & Co., Inc.
  - 8.5.8.1. Participant's Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Recent Developments/ Strategic Initiatives